-
Press Release
Novartis completes divestment of ‘front of eye’ ophthalmology assets
-
Press Release
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
-
Featured News
World Sight Day 2022: Raising awareness on the importance of eye health -
Press Release
Novartis announces European Commission approval of Beovu® for people living with diabetic macular edema
-
Press Release
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
-
Press Release
Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
-
Featured News
World Sight Day 2021 -
Story
Restoring vision and hope to thousands in Southeast Asia -
Press Release
Novartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks
-
Press Release
Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
-
Press Release
Novartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision
-
Press Release
Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss